VoltarelliJC, CouriCE, StracieriAB, et al.Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA, 2007; 297: 1568–1576.
2.
SnarskiE, MilczarczykA, HalaburdaK, et al.Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations. Bone Marrow Transplant, 2016; 51: 398–402.
3.
LiL, ShenS, OuyangJ, HuY, HuL, CuiW, ZhangN, ZhugeYZ, ChenB, XuJ, ZhuD. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves b-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab, 2012; 97: 1729–1736.
4.
LudvigssonJ, FaresjöM, HjorthM, et al.GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med, 2017; 359: 1909–1920.
5.
WherrettDK, BundyB, BeckerDJ, et al.for the Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet, 2011; 378: 319–327.
6.
LudvigssonJ, KriskyD, CasasR, et al.GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med, 2012; 366: 433–442.
7.
HallerM, AtkinsonM, SchatzD. More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes. N Engl J Med, 2017; 377: 403–405.
8.
TaviraB, CheramyM, AxelssonS, ÅkermanL, LudvigssonJ, CasasR. Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD65-induced immune response. Diabetologia, 2017; 60: 1276–1283.
9.
PhamMN, GibsonC, RydénAK, et al.Oral insulin (human, murine, or porcine) does not prevent diabetes in the non-obese diabetic mouse. Clin Immunol, 2016; 164: 28–33.
10.
MoyaR, RobertsonHK, PayneP, NarsaleA, KoziolJ, the Type 1 Diabetes TrialNet Study Group, and DaviesJD. A pilot study showing associations between frequency of CD4+ memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes. Clin Immunol, 2016; 166–167: 72–80.
